I mean, by removing those two pieces of the business that have been historical burners and while we’d like to continue R&D at some point in the future, it’s not in the cards anytime soon. And so we are going to be squarely focused on operating that strongly EBITDA positive segment. That segment, by the way, fully supports G&A for all of our public company costs, all of our overhead, staffing, and so forth. So we are comfortable saying, as a go-forward company, we’re a prescription business. And ultimately, revenues will be — on the Consumer piece, obviously they’re down year-over-year that’s by design. You’ll see the Consumer business sort of drop-off and the hope is that goes to zero, but the burn will obviously go to zero as well. And so we’ll really be relying upon the growth from the Rx sector — segment to propel the company forward.
Mark Oki: Yeah, we just want to stress, the Rx business again absorbs all of the, kind of, public company standalone business expenses. When you carve out, if you look at our earnings releases, if you take out [de novos] (ph) and you take out pipeline spending, that is the remaining company. There’s no — there’s very little expense that the Rx business would pick up with the closing down of the Consumer Health business.
Unidentified Analyst: Excellent. Thanks for answering that question. Just a short follow-up question. Could you expand on your cash needs moving forward?
Mark Oki: Yeah, so we think we’re in good shape for cash. We have the appropriate amount of cash and borrowing capacity to fund operations. We do have the debt that comes up in January of 2025 and we have some other liabilities that will have to be paid over time. We — the big bogey is the refinancing of the Avenue debt. And so, we will be releasing our 10-K next week. We expect that we will continue to have a growing concern opinion. But we think it’s primarily focused around again the Avenue debt as we don’t currently have it refinanced. We don’t want to be in a situation where we take off the going concern and then immediately jump back into it as that debt becomes current. So you will see that in our 10-K. But, funding operations, we are very comfortable with. And then most of our other non-debt liabilities are managed at our discretion. We may have to pay a little bit of interest on it but we don’t have to pay it all at once.
Unidentified Analyst: Excellent, thanks for answering my questions, helpful. Thank you.
Josh Disbrow: Thank you.
Operator: Thank you. There were no other questions at this time. I would now like to hand the call back to management for closing remarks.
Josh Disbrow: Great. Thanks very much. Again, we appreciate everyone’s participation on today’s call. We appreciate your commitment to the future of Aytu. We are very pleased with this year’s results, with this last quarter’s results. We’re really excited about the progress we’re making on all fronts as we’ve shared. We are also very pleased with how we’re starting-off fiscal ‘24 as we look at prescription trends, factory sales units, and the overall progress we’re making to further consolidate our expenses and improve margins. So, again, thanks for joining us today. We look forward to updating you following the closeout of our fiscal Q1 for fiscal ‘24, which we’ll report out in November. Until then, I wish you all a good afternoon and good evening. Thanks again for joining and goodbye.
Operator: Thank you. This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.
Mark Oki: Thanks everyone.
